J Physiol. 2023 Mar 31.
Immobilization leads to muscle wasting and insulin resistance, particularly during aging. Undercarboxylated osteocalcin (ucOC) has been suggested to improve muscle mass and glucose metabolism. Bisphosphonates, an anti-osteoporosis treatment, might protect muscle wasting independent of ucOC. We hypothesize that the combination of ucOC and ibandronate (IBN) treatments has superior protective effects against immobilization-induced muscle wasting and insulin resistance than either treatment alone. C57BL/6J mice were hindlimb-immobilized for two weeks, with injections of vehicle, ucOC (90 ng/g daily) and/or IBN (2 μg/g weekly). Insulin/oral glucose tolerance tests (ITT/OGTT) were performed. Immediately after immobilization, muscles (extensor digitorum longus [EDL], soleus, tibialis anterior [TA], gastrocnemius, and quadriceps) were isolated and measured for muscle mass. Insulin-stimulated glucose uptake (EDL and soleus) was examined. Phosphorylation/expression of proteins in anabolic/catabolic pathways were examined in quadriceps. Primary human myotubes derived from older adult muscle biopsies were treated with ucOC and/or IBN, then signaling proteins were analyzed. Combined treatment, but not individual treatments, significantly increased muscle weight/body weight ratio in immobilized soleus (31.7 %; p = 0.013) and quadriceps (20.0 %; p = 0.0008) muscles, concomitant with elevated p-Akt (S473)/Akt ratio (p = 0.0047). Combined treatment also enhanced whole-body glucose tolerance (16.6 %; p = 0.0011). In human myotubes, combined treatment stimulated greater activation of ERK1/2 (p = 0.0067 and 0.0072) and mTOR (p = 0.036), and led to a lesser expression of Fbx32 (p = 0.049) and MuRF1 (p = 0.048), than individual treatments. These findings suggest a potential therapeutic role of ucOC and bisphosphonates combination in protecting against muscle wasting induced by immobilization and aging. KEY POINTS: Undercarboxylated osteocalcin (ucOC) has been suggested to improve muscle mass and glucose metabolism. Bisphosphonates, an anti-osteoporosis treatment, might protect muscle wasting independent of ucOC. The combination treatment of ucOC and ibandronate was shown to exert greater therapeutic effect against immobilization-induced muscle wasting, and lead to greater activation of anabolic pathway and less expression of catabolic signaling proteins in myotubes derived from older adults, compared to individual treatments. The combination treatment was found to improve whole-body glucose tolerance. Our findings suggest a potential therapeutic role of ucOC and bisphosphonates combination in protecting against muscle wasting induced by immobilization and aging. Abstract figure legend Undercarboxylated osteocalcin (ucOC) and ibandronate (IBN) combination improves muscle mass and glucose disposal. Two weeks of hindlimb immobilization in mice led to leg muscle atrophy as well as muscle insulin resistance. Injections of both undercarboxylated osteocalcin (intraperitoneal [IP]) and ibandronate (subcutaneous [SC]) alleviated muscle wasting in a muscle type-specific manner. In addition, this combination treatment improved glucose disposal in mice. In both immobilized mouse muscle and human primary myotubes derived from older adults, the combination treatment with ucOC and IBN resulted in greater activation of proteins involved in anabolic signaling pathway, including Akt and mTORC1. In primary myotubes, this treatment reduced expression of proteins involved in catabolic signaling pathway, such as Fbx32 and MuRF1. These findings suggest that ucOC and bisphosphonates combination has a potential in treating muscle wasting and insulin resistance induced by immobilization and aging. This article is protected by copyright. All rights reserved.
Keywords: bisphosphonates; glucose metabolism; hindlimb immobilization; muscle wasting; undercarboxylated osteocalcin